What was Alembic Pharma's fourth-quarter consolidated profit and how did it compare year-on-year?

Alembic Pharmaceuticals' consolidated profit for the quarter ended March 31 rose by 29.2% to 2.03 billion rupees ($21.12 million), up from 1.57 billion rupees a year ago.

What drove the growth in Alembic Pharma's U.S. generics business in the fourth quarter?

Revenue from Alembic Pharma's U.S. generics business jumped 11% to 5.64 billion rupees, driven by key product launches such as the UTI treatment drug Pivya and gains in market share across select therapies.

India's Alembic Pharma quarterly profit rises on strong U.S. generics demand

May 15, 2026

Alembic Pharmaceuticals posted a 29.2% rise in fourth-quarter profit to 2.03 billion rupees, driven by strong U.S. generics demand. Overall revenue increased 4.4%, contrasting with weaker results from larger rivals Cipla and Dr Reddy's.

reuters

2026-05-15

India's Alembic Pharma quarterly profit rises on strong U.S. generics demand

2026-09-16

Indian Shares Open Flat After Fed Rate Hike; NSE IPO in Focus

India's Alembic Pharma quarterly profit rises on strong U.S. generics demand

FAQ